Skip to main content
Lobe Sciences Ltd. logo

Lobe Sciences Ltd. — Investor Relations & Filings

Ticker · LOBE ISIN · CA53946V2066 CSE Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2026-05-06 Interim / Quarterly Rep…
Country CA Canada
Listing CSE LOBE

About Lobe Sciences Ltd.

https://www.lobesciences.com/

Lobe Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing transformative therapies for rare and underserved diseases with unmet medical needs. The company utilizes innovative technologies, including lipid technology, to advance its pipeline. Through its subsidiary, Cynaptec Pharmaceuticals, Lobe is developing L-130 (Conjugated Psilocin™), a patented formulation engineered to provide the therapeutic effects of psilocybin without the hallucinogenic properties. Its second subsidiary, Altemia, Inc., develops S-100, a novel medical food product intended for the dietary management and treatment of Sickle Cell Disease. The company's research targets conditions such as Chronic Cluster Headache and Sickle Cell Disease.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of the company's unaudited interim financial results for the second quarter of fiscal 2026, including financial highlights, operational updates, CEO comments, and subsequent financing events. It contains substantive financial data such as cash, working capital, R&D expenses, operating cash flow, and net loss for the quarter. The document also references the interim financial statements and management's discussion and analysis for Q2 2026, indicating it is a comprehensive interim report rather than a brief announcement or certification. The presence of detailed financial results and operational progress for a period shorter than a full fiscal year aligns with the definition of an Interim / Quarterly Report (IR). Therefore, the appropriate classification is IR with high confidence. Q2 2026
2026-05-06 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2026-04-29 English
Interim MD&A - English.pdf
Regulatory Filings
2026-04-29 English
Interim financial statements/report – English.pdf
Regulatory Filings
2026-04-29 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 87% confidence The document is a Canadian securities regulatory form (Form 45-106F1 Report of Exempt Distribution) used to report an exempt distribution under NI 45-106. It is not an annual or quarterly financial report, earnings release, AGM material, management change, or other specific item in our taxonomy. It is a mandatory regulatory filing for exempt distributions and does not fall under alternative categories. Therefore, it is classified under Regulatory Filings (RNS).
2026-04-24 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 92% confidence The document is a Canadian securities regulatory form (Form 45-106F1) reporting an exempt distribution of shares (14,615,384 securities for C$950,000). It is not an earnings release, annual/interim report, management discussion, or AGM material, but rather a specialized regulatory filing under NI 45-106. This does not fit any other narrow category, so it falls under the general “Regulatory Filings” fallback.
2026-04-24 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.